UNCY Stock Analysis: Buy, Sell, or Hold?
UNCY - Unicycive Therapeutics, Inc. Common Stock
$7.94
0.08 (1.02%)
▲
5d:
+3.52%
30d:
+19.4%
90d:
+18.68%
HOLD
MODERATE Confidence
Analysis Updated: May 8, 2026 12:00 AM ET
Earnings: May 13, 2026
2d
Smart Money Accumulation
UNCY is down 7.1% this week, but smart money is accumulating calls. Top strike: $7.5 2026-07-17 with 791 OI. Call ratio: 83% View Scanner →
Strength: 6.8/10
Get Alerted When UNCY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: UNCY trades at premium valuation expecting 4.3% growth. Hold existing positions but don't chase. Wait for better entry.
📊 HOLD: UNCY trades at premium valuation expecting 4.3% growth. Hold existing positions but don't chase. Wait for better entry.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$13.32
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$8.27
4.0% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 1.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: UNCY is currently trading at $7.94, which is considered extended relative to its 30-day fair value range of $6.58 to $7.54. From a valuation perspective, the stock is trading at a premium (Forward PE: 1.2) compared to its historical average (1.0). At these levels, the market is pricing in 4.3% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, UNCY is in a strong uptrend. Immediate support is located at $7.05, while resistance sits at $8.34.
Market Sentiment: UNCY has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $41.31 (+420.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, UNCY is in a strong uptrend. Immediate support is located at $7.05, while resistance sits at $8.34.
Market Sentiment: UNCY has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $41.31 (+420.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$6.58 -
$7.54
Company Quality Score
68/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
56.2%
All Signals
- BEARISH: Price extended above range (+5.3% above its trading range)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 420.3% below Wall St target ($41.31)
- NEUTRAL: Trading at premium valuation - market expects 4.3% growth which is achievable
Trading Range Analysis
30-Day Trading Range
$6.58 -
$7.54
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$7.05
Resistance Level
$8.34
Current Trend
Strong Uptrend
Technical data as of
May 8, 2026
Fundamental Context
Forward P/E (Next Year Est.)
1.16
Wall Street Target
$41.31
(+420.3%)
Valuation Premium vs History
+4.3% premium
PE vs Historical
1.2 vs 1.0
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+4.3%
(market-implied from PE analysis)
1-Year Target
$8.28
(+4%)
2-Year Target
$8.64
(+9%)
3-Year Target
$9.01
(+14%)
3-Yr Target (if PE normalizes)
(PE: 1→1)
PE COMPRESSION
$7.76
(-2%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.9, Growth: 683760.0%)
$506.38
(+6278%)
Base:
(SPY PE: 1.2, Growth: 683760.0%)
$26.80
(+238%)
Bear:
(PE: 1.0, Growth: 683760.0%)
$22.78
(+187%)
Share & Embed Analysis
Last updated: May 10, 2026 4:12 PM ET
Data refreshes hourly during market hours. Next update: 5:12 PM
Data refreshes hourly during market hours. Next update: 5:12 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is UNCY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$26 | 56 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 56 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$51 | 63 BUY |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$130 | 48 HOLD |
